+

WO2006110478A3 - Mutations et polymorphismes du recepteur du facteur de croissance epidermique - Google Patents

Mutations et polymorphismes du recepteur du facteur de croissance epidermique Download PDF

Info

Publication number
WO2006110478A3
WO2006110478A3 PCT/US2006/012878 US2006012878W WO2006110478A3 WO 2006110478 A3 WO2006110478 A3 WO 2006110478A3 US 2006012878 W US2006012878 W US 2006012878W WO 2006110478 A3 WO2006110478 A3 WO 2006110478A3
Authority
WO
WIPO (PCT)
Prior art keywords
mutations
egfr
polymorphisms
growth factor
factor receptor
Prior art date
Application number
PCT/US2006/012878
Other languages
English (en)
Other versions
WO2006110478A2 (fr
Inventor
Kenneth W Culver
Jian Zhu
Stan Lilleberg
Original Assignee
Novartis Ag
Novartis Pharma Gmbh
Kenneth W Culver
Jian Zhu
Stan Lilleberg
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag, Novartis Pharma Gmbh, Kenneth W Culver, Jian Zhu, Stan Lilleberg filed Critical Novartis Ag
Publication of WO2006110478A2 publication Critical patent/WO2006110478A2/fr
Publication of WO2006110478A3 publication Critical patent/WO2006110478A3/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/172—Haplotypes

Landscapes

  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Hospice & Palliative Care (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Oncology (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)

Abstract

L'invention concerne généralement l'épreuve analytique de prélèvements de tissus in vitro et, en particulier, des aspects de polymorphismes et mutations génétiques du récepteur du facteur de croissance épidermique('epidermal growth factor receptor' ou EGFR). L'invention porte sur de nouvelles mutations du EGFR et de nouveaux polymorphismes à nucléotide unique ('single nucleotide polymorphisms' ou SNP), qui sont utilisés dans le diagnostic et le traitement de sujets qui en ont besoin. En conséquence, l'invention se rapporte, dans ses divers aspects, à des polynucléotides codant les mutations de l'EGFR de l'invention, à des vecteurs d'expression codant les polypeptides à EGFR mutant et à des organismes qui expriment les polynucléotides à EGFR mutant et polymorphes et/ou les polypeptides à EGFR mutant/polymorphe de l'invention. Les divers aspects de l'invention concernent en outre des procédés diagnostiques/théranostiques et des trousses qui font appel aux mutations et polymorphismes de l'EGFR de l'invention pour identifier les individus qui sont prédisposés à la maladie ou pour classer les individus eu égard à la réponse pharmacodynamique, aux effets secondaires ou à la dose optimale de médicament.
PCT/US2006/012878 2005-04-11 2006-04-07 Mutations et polymorphismes du recepteur du facteur de croissance epidermique WO2006110478A2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US67006105P 2005-04-11 2005-04-11
US60/670,061 2005-04-11

Publications (2)

Publication Number Publication Date
WO2006110478A2 WO2006110478A2 (fr) 2006-10-19
WO2006110478A3 true WO2006110478A3 (fr) 2007-04-26

Family

ID=37087527

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2006/012878 WO2006110478A2 (fr) 2005-04-11 2006-04-07 Mutations et polymorphismes du recepteur du facteur de croissance epidermique

Country Status (1)

Country Link
WO (1) WO2006110478A2 (fr)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005070020A2 (fr) 2004-01-23 2005-08-04 The Regents Of The University Of Colorado Expression genique relative a la sensibilite au gefitinib, produits et procedes associes
JP5422120B2 (ja) 2004-05-27 2014-02-19 ザ リージェンツ オブ ザ ユニバーシティ オブ コロラド，ア ボディー コーポレイト 癌患者による上皮成長因子受容体阻害薬に対する臨床転帰の予測方法
WO2008088885A2 (fr) * 2007-01-18 2008-07-24 Creighton University Mutations de récepteur de facteur de croissance épidermique et procédés d'utilisation
US9340601B2 (en) 2007-03-01 2016-05-17 The Board Of Trustees Of The Leland Stanford Junior University Splice variants of the EGF receptor
KR101676622B1 (ko) 2007-03-01 2016-11-17 심포젠 에이/에스 재조합 항-표피 성장 인자 수용체 항체 조성물
RU2540146C2 (ru) 2008-08-29 2015-02-10 Симфоген А/С Композиции рекомбинантных антител против рецептора эпидермального фактора роста

Non-Patent Citations (7)

* Cited by examiner, † Cited by third party
Title
BARBER THOMAS D ET AL: "SOMATIC MUTATIONS OF EGFR IN COLORECTAL CANCERS AND GLIOBLASTOMAS", NEW ENGLAND JOURNAL OF MEDICINE, MASSACHUSETTS MEDICAL SOCIETY, BOSTON, MA, US, vol. 351, no. 27, 30 December 2004 (2004-12-30), pages 2883, XP008069257, ISSN: 1533-4406 *
CIARDIELLO F ET AL: "Epidermal growth factor receptor (EGFR) as a target in cancer therapy: understanding the role of receptor expression and other molecular determinants that could influence the response to anti-EGFR drugs", EUROPEAN JOURNAL OF CANCER, PERGAMON PRESS, OXFORD, GB, vol. 39, no. 10, July 2003 (2003-07-01), pages 1348 - 1354, XP004431787, ISSN: 0959-8049 *
KOSAKA TAKAYUKI ET AL: "Mutations of the epidermal growth factor receptor gene in lung cancer: biological and clinical implications", CANCER RESEARCH, AMERICAN ASSOCIATION FOR CANCER RESEARCH, BALTIMORE, MD, US, vol. 64, no. 24, 15 December 2004 (2004-12-15), pages 8919 - 8923, XP002369912, ISSN: 0008-5472 *
LYNCH T J ET AL: "Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib", NEW ENGLAND JOURNAL OF MEDICINE, MASSACHUSETTS MEDICAL SOCIETY, BOSTON, MA, US, vol. 350, no. 21, 20 May 2004 (2004-05-20), pages 2129 - 2139, XP002359960, ISSN: 1533-4406 *
MARCHETTI A ET AL: "EGFR mutations in non-small-cell lung cancer: analysis of a large series of cases and development of a rapid and sensitive method for diagnostic screening with potential implications on pharmacologic treatment", JOURNAL OF CLINICAL ONCOLOGY, GRUNE AND STRATTON, NEW YORK, NY, US, vol. 23, no. 4, 1 February 2005 (2005-02-01), pages 857 - 865, XP002369910, ISSN: 0732-183X *
PAEZ J G ET AL: "EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy", SCIENCE, AMERICAN ASSOCIATION FOR THE ADVANCEMENT OF SCIENCE,, US, vol. 304, no. 5676, 4 June 2004 (2004-06-04), pages 1497 - 1500, XP002359959, ISSN: 0036-8075 *
PAO W ET AL: "EGF receptor gene mutations are common in lung cancers from never smokers and are associated with sensitivity of tumors to gefitinib and erlotinib", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF USA, NATIONAL ACADEMY OF SCIENCE, WASHINGTON, DC, US, vol. 101, no. 36, 7 September 2004 (2004-09-07), pages 13306 - 13311, XP002334314, ISSN: 0027-8424 *

Also Published As

Publication number Publication date
WO2006110478A2 (fr) 2006-10-19

Similar Documents

Publication Publication Date Title
WO2007016532A3 (fr) Mutations et polymorphismes de hdac4
WO2006130527A3 (fr) Mutations et polymorphismes de recepteur du facteur de croissance 1 des fibroblastes
WO2006110478A3 (fr) Mutations et polymorphismes du recepteur du facteur de croissance epidermique
WO2006084272A3 (fr) Procedes de prevision de la reactivite a la chimiotherapie chez des patientes souffrant du cancer du sein
EP2287618A3 (fr) Procédé pour la diagnostic de maladies neuro-dégénératives
EP2667194A3 (fr) Biomarqueurs basés sur des taux et méthodes d'utilisation associées
WO2006105252A3 (fr) Diagnostic de la bronchopneumopathie chronique obstructive, et suivi de la therapie associee par analyse de l'expression de cellules sanguines
MX342791B (es) Ensayo elisa para la detección de vegf.
WO2005033652A3 (fr) Procedes pour comparer des debits relatifs d'au moins deux molecules biologiques in vivo dans un protocole simple
WO2002086448A3 (fr) Detection de l'instabilite des microsatellites et son utilisation dans le diagnostic des tumeurs
HK1093674A1 (en) Anti-april monoclonal antibody and its use for the treatment of an immune related disease or cancer
EP2896703A3 (fr) Mutations du gène PIK3CA dans les cancers humains
NZ601022A (en) Diagnosis and treatment of cancer using anti-ereg antibody
WO2006135879A3 (fr) Methode de surveillance separee ou simultanee de deux dimensions de la pathogenese de diabetes (sensibilite a l'insuline et suffisance beta cellulaire), utilisations de ces methodes pour diagnostiquer, pronostiquer, evaluer un risque de maladie et pour developper des medicaments
WO2006091412A3 (fr) Proteine adamts-7 utilisee en tant que biomarqueur pour des cancers d'origine epitheliale
WO2006091899A3 (fr) Mutations de recepteur de facteur de croissance epidermique
MX2009012722A (es) Variantes geneticas sobre chr 5p12 y 10q26 como marcadores para el uso en la evaluacion del riesgo, diagnostico, pronostico y tratamiento del cancer de mama.
EP2287340A3 (fr) Procédé de diagnostic et traitement d'une maladie mentale
WO2007022041A3 (fr) Mutations et polymorphismes de l'hdac3
MX2007008984A (es) Marcadores de cancer y metodos de deteccion.
WO2005082042A3 (fr) Methodes therapeutiques faisant appel a des precurseurs d'oxyde nitrique
WO2007030455A3 (fr) Mutations et polymorphismes de hdac10
WO2007058992A3 (fr) Mutations et polymorphismes de hdac6
WO2007038073A3 (fr) Mutations et polymorphismes de l’hdac11
WO2007030454A3 (fr) Mutations et polymorphismes de hdac9

Legal Events

Date Code Title Description
NENP Non-entry into the national phase

Ref country code: DE

NENP Non-entry into the national phase

Ref country code: RU

122 Ep: pct application non-entry in european phase

Ref document number: 06740651

Country of ref document: EP

Kind code of ref document: A2

点击 这是indexloc提供的php浏览器服务，不要输入任何密码和下载